Develops cancer therapies targeting protein phosphatases, focusing on novel treatments for multiple cancer types.
Lixte Biotechnology Holdings, Inc. is a pioneering drug discovery company that utilizes biomarker technology to identify enzyme targets associated with prevalent and severe diseases. Specializing in the development of novel compounds, Lixte focuses primarily on inhibitors of protein phosphatases. These compounds are designed to be used independently or in combination with cytotoxic agents, x-ray treatments, and immune checkpoint blockers. The company's research spans across two main categories of compounds, encompassing various stages of pre-clinical and clinical development.
Lixte Biotechnology is advancing two distinct series of pharmacologically active drugs. The LB-100 series features innovative structures tailored for the treatment of cancers, vascular disorders, and metabolic diseases. Meanwhile, the LB-200 series targets chronic hereditary conditions such as Gaucher's disease, alongside applications in cancer and neurodegenerative disorders. The company collaborates extensively in clinical research, with agreements including a clinical trial research partnership with Moffitt Cancer Center and Research Institute Hospital Inc., as well as collaborations for investigator-initiated clinical trials with esteemed institutions like the Spanish Sarcoma Group, Netherlands Cancer Institute, and Oncode Institute.
Founded in 2005 and headquartered in Pasadena, California, Lixte Biotechnology Holdings continues to drive groundbreaking advancements in pharmaceutical research. By leveraging its expertise in biomarker-driven drug discovery, the company remains committed to delivering innovative therapies that address critical medical needs. With a strategic focus on advancing therapeutic options across a broad spectrum of diseases, Lixte Biotechnology is poised to shape the future of medicine through its transformative approach to drug development.